Pharmaceutical Executive Daily: Pfizer's Stock Drops Following 2026 Revenue Projections Release
Dec 18, 2025, 04:26 PM
Share
Subscribe
In today’s Pharmaceutical Executive Daily, Pfizer discloses its 2026 revenue expectations, a bipartisan group of House Republicans moves to force a vote on extending ACA tax credits, and new collaboration and merger activity highlights continued dealmaking momentum across biopharma.